ReviewMolecular pathology : MP2001
The aetiology of idiopathic Parkinson's disease.
Review in Molecular pathology : MP, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 47 citations in OpenAlex.
- In vivo overexpression of synaptogyrin-3 promotes striatal synaptic dopamine uptake in LRRK2Brain and behavior · 2023Article
- Transcriptional Regulation of the Synaptic Vesicle Protein Synaptogyrin-3 (International journal of molecular sciences · 2022Article
- Modulation of Neuroinflammation by the Gut Microbiota in Prion and Prion-Like Diseases.Pathogens (Basel, Switzerland) · 2021Review
- JNK inhibition of VMAT2 contributes to rotenone-induced oxidative stress and dopamine neuron death.Toxicology · 2015Article
- Oxidative stress-dependent changes in immune responses and cell death in the substantia nigra after ozone exposure in rat.Frontiers in aging neuroscience · 2015Article
- Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.Molecular neurobiology · 2012Review
- In silico QTL mapping of basal liver iron levels in inbred mouse strains.Physiological genomics · 2011Article
- Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol.Chemical research in toxicology · 2009Article
- Model fusion, the next phase in developing animal models for Parkinson's disease.Neurotoxicity research · 2007Review
- Apoptotic natural cell death in developing primate dopamine midbrain neurons occurs during a restricted period in the second trimester of gestation.Experimental neurology · 2007Article
- Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2006Article
- Pathological proteins in Parkinson's disease: focus on the proteasome.Journal of molecular neuroscience : MN · 2004Review
- Etiology of Parkinson's disease: Genetics and environment revisited.Proceedings of the National Academy of Sciences of the United States of America · 2002Review
- The genetics of Parkinson's disease.Current neurology and neuroscience reports · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Agents potentially involved in the aetiology of idiopathic Parkinson's disease are discussed. These include factors regulating dopaminergic neurogenesis (Nurr 1, Ptx-3, and Lmx1b) and related proteins, together with genes involved in familial Parkinson's disease (alpha synuclein, parkin, and ubiquitin carboxy terminal hydroxylase L1), and endogenous and environmental agents.
Indexed as
Identifiers
11724911PMC1187126W1882113374What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.